Introduction {#s1}
============

Osteoporosis is a pervasive disorder characterized by skeletal fragility and microarchitectural deterioration that predisposes individuals to bone fractures. The disease has a significant global impact, affecting an estimated 200 million people worldwide and exerts a heavy economic burden. Moreover, disease prevalence is projected to rise by approximately 50% within the next ten years ([@bib3]). Therefore, understanding the pathogenesis of osteoporosis is an urgent matter to develop better treatments for this debilitating disease.

Bone remodeling is carried out by the coordinated actions of the bone-forming osteoblasts (OBs) and the bone-resorbing osteoclasts (OCs). Disorders of skeletal deficiency such as osteoporosis are typically characterized by enhanced osteoclastic bone resorption relative to bone formation, thereby resulting in net bone loss. Although significant progress has been made in understanding the pathological role of OCs, the molecular pathways that drive OC differentiation remains an area needing further investigation.

Regulators of G-protein Signaling (RGS) are a family comprised of more than thirty proteins that share the eponymous and functionally conserved RGS domain; these proteins play a classical role in attenuating G protein-coupled receptor signaling through its GTPase-accelerating protein activity to inactivate the Gα subunit ([@bib35]; [@bib23]). RGS proteins are multifunctional proteins that can contribute to various cellular processes including cell differentiation. Rgs12 is unique in that it is the largest protein in its family. In addition to the RGS domain, Rgs12 contains a PSD-95/Dlg/ZO1 (PDZ) domain, a phosphotyrosine-binding (PTB) domain, a tandem Ras-binding domain (RBD1/2), and a GoLoco interaction motif. The multi-domain architecture of Rgs12 is thought to facilitate its role as a scaffolding protein in complexes in which multiple signaling pathways might converge ([@bib48]; [@bib40]; [@bib47]; [@bib52]; [@bib41]).

Reactive oxygen species (ROS) are produced as a normal byproduct of cellular metabolism ([@bib8]) and forms the basis Denham Harman's free radical theory of aging, which perhaps is the most enduring model of aging. The theory of aging postulates that the gradual accumulation of damage inflicted by ROS eventually manifests as degenerative diseases associated with aging ([@bib15]; [@bib26]). In addition to longevity, ROS have been implicated in the management and prevention of cancers, cardiovascular diseases, macular degeneration, Alzheimer's disease, arthritis, and many other tissues---to which the bone is no exception ([@bib34]; [@bib11]).

More recent studies have shown that RANKL-induced ROS are indispensable for OC differentiation ([@bib8]; [@bib27]; [@bib25]; [@bib5]). ROS at high levels induce oxidative stress, which if left unchecked becomes deleterious to cell. At low concentrations, however, ROS have been shown to participate in signaling events in OCs, including the RANKL-dependent activation of mitogen-activated protein kinases (MAPKs), phospholipase C gamma (PLCγ), nuclear factor kappa B (NFκB), and \[Ca^2+^\] oscillations; all of which contribute to the activation of nuclear factor of T-cells (NFAT), the master regulator of OC differentiation. Multiple lines of evidence have consistently shown that suppression of ROS by various means could inhibit OC differentiation ([@bib27]; [@bib25]; [@bib5]). In particular, RANKL-dependent activation of PLCγ, \[Ca^2+^\] oscillations, and NFAT were abrogated when OC precursors were treated with the antioxidant N-acetylcysteine (NAC) ([@bib25]). Furthermore, our previous studies demonstrated that Rgs12 silencing could inhibit PLCγ activation, \[Ca^2+^\] oscillations, and the expression of NFATc1 and its downstream factors ([@bib55]). Hence, these findings led us to hypothesize that Rgs12 may play a role in regulating the cellular redox state, thereby controlling OC differentiation.

Results {#s2}
=======

Targeted deletion of Rgs12 selectively reduced osteoclast formation and increased trabecular bone mass {#s2-1}
------------------------------------------------------------------------------------------------------

To assess the role of Rgs12 in OC differentiation and bone remodeling in vivo, we generated a conditional gene knockout mouse model by crossing *Rgs12^flox/flox^* mice with Lysozyme M-cre (LyzM^Cre^) transgenic mice (Rgs12 cKO). The LyzM promoter-driven Cre expression targets *Rgs12* gene deletion to cells of the myeloid lineage, including monocytes/macrophages ([@bib2]; [@bib10]). Micro-CT analysis of the distal femurs obtained from *Rgs12^flox/flox^* and *Rgs12^+/+^;LyzM^Cre^* showed no statistically difference in bone histomorphometry ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). *Rgs12^flox/flox^* mice were used as controls. The Cre-lox-mediated deletion of the *Rgs12* gene was confirmed by PCR amplification of spleen genomic DNA ([Figure 1A](#fig1){ref-type="fig"}) and qPCR to measure *Rgs12* transcripts in isolated bone marrow macrophages (BMMs) ([Figure 1B](#fig1){ref-type="fig"}), thereby confirming our mouse Rgs12 cKO model.

![Rgs12-deficient mice exhibit increased trabecular bone mass attributed to impaired osteoclastogenesis.\
(**A**) PCR of splenic genomic DNA amplifying the deletion allele in Rgs12 cKO and control mice. (**B**) qPCR analysis of Rgs12 mRNA levels normalized to β-actin in BMMs obtained from Rgs12 cKO and control mice. Histological assessment of bone morphology and microarchitecture of Rgs12 cKO and control mice include: (**C**) H and E staining of proximal tibiae (N = 4), (**D**) 3D micro-computed tomography (micro-CT) imaging and (**E--I**) quantitative measurement of femoral trabecular bone (N~Control~ = 11, N~Rgs12cKO~=7), (**J**) TRAP staining and quantitation of (**K**) OBs and (**L--M**) OCs in distal femurs (N = 5), and (**N**) dynamic histomorphometry analysis by double-calcein labeling and (**O--P**) quantitative measurements of bone formation in distal femurs (N = 5). All results are means ± SD (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). *VOX-BV/TV, bone volume to tissue volume (voxel count); TRI-SMI, structure model index; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; N.Ob/B.Pm, osteoblast number per bone perimeter; N.Oc/B.Pm, osteoclast number per bone perimeter; TRAP, tartrate-resistant acid phosphatase; MNC, multinucleated cell; MAR, mineral apposition rate; BFR/BS, bone formation rate per bone surface*.\
10.7554/eLife.42951.005Figure 1---source data 1.Excel sheet contains the numerical data and summary statistics representing the micro-CT data in [Figure 1E--I](#fig1){ref-type="fig"}.](elife-42951-fig1){#fig1}

Rgs12 cKO mice exhibited increased trabecular bone mass, evident in the hematoxylin and eosin (H and E)-stained sections of the proximal tibia ([Figure 1C](#fig1){ref-type="fig"}) and 3D micro-computed tomography (micro-CT) visualization of the femoral trabecular bone morphology and microarchitecture ([Figure 1D](#fig1){ref-type="fig"}). Quantitative micro-CT measurements further demonstrated statistically significant increases in bone volume (VOX-BV/TV), accompanied by increases in both trabecular number (Tb.N) and thickness (Tb.Th), and reduced trabecular separation (Tb.Sp) ([Figure 1E--I](#fig1){ref-type="fig"}). Therefore, the targeted deletion of Rgs12 in mice resulted in increased bone mass.

To determine whether the high bone mass was a consequence of decreased osteoclast numbers or increased osteoblast numbers in vivo, we quantified the cell numbers from distal femurs stained for tartrate-resistant acid phosphatase (TRAP) ([Figure 1J](#fig1){ref-type="fig"}). The histological assessment clearly demonstrates no difference in osteoblast numbers between Rgs12 cKO and control bone tissues ([Figure 1K](#fig1){ref-type="fig"}) whereas the number of TRAP^+^ multinucleated cells were markedly reduced in Rgs12-deficient samples ([Figure 1L and M](#fig1){ref-type="fig"}). Furthermore, a dynamic histomorphometric analysis by double calcein labeling to measure bone growth over time shows that the rate of bone formation was comparable between Rgs12 cKO and control mice ([Figure 1N--P](#fig1){ref-type="fig"}). Consequently, the results collectively support the specific role of Rgs12 in OCs and emphasizes the gene's importance in bone remodeling.

Rgs12 promotes osteoclast formation and bone resorptive activity {#s2-2}
----------------------------------------------------------------

To further evaluate the role of Rgs12 in osteoclastogenesis, OC precursors isolated from wild-type mice (*Rgs12^+/+^*) were differentiated using macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL), the two cytokines necessary and sufficient to induce osteoclast formation. Rgs12 protein and transcript levels were dramatically upregulated upon stimulation by the differentiation factors, and seem to consistently increase into OC maturity at day 5 ([Figure 2A--B](#fig2){ref-type="fig"}). A comparison of osteoclastogenic potential between precursors derived from Rgs12 cKO and control mice show that while control BMMs differentiated into large, TRAP^+^ multinucleated OCs, Rgs12-deficient precursor cells showed a reduction in the number of OCs containing 6--9 nuclei and 10+ nuclei, which were also visibly smaller ([Figure 2C--D](#fig2){ref-type="fig"}). We also probed into the overall bone resorptive activity and found that Rgs12-deficient OCs have significantly reduced ability to resorb calcium phosphate surfaces ([Figure 2E--F](#fig2){ref-type="fig"}). Complementing our Rgs12 knockout model, we generated an Rgs12 overexpression OC model in which the transformed murine macrophage-like RAW264.7 cells were stably-transfected with a vector carrying a recombinant N-terminus FLAG-tagged Rgs12 gene (Flag-Rgs12). Rgs12 overexpression in RAW264.7 cells was confirmed by western blotting ([Figure 2G](#fig2){ref-type="fig"}). Using this cell model, we next determined whether Rgs12 overexpression could promote OC formation. Contrasting our findings in Rgs12 cKO primary cells, we found that the overexpression of Rgs12 in RAW264.7 cells led to an increased number of OCs with 10+ nuclei ([Figure 2H--I](#fig2){ref-type="fig"}). We also observed significantly decreased numbers of smaller OCs containing 3--5 and 6--9 nuclei in Rgs12 overexpressing cells, presumably because most of the smaller OCs have fused to form large OCs containing 10+ nuclei. A previous study investigating the relationship between OC size and state of resorptive activity found that a greater proportion of large OCs were active whereas non-resorbing OCs were on average smaller ([@bib28]). In our study, the quantification of the mean areas of OCs with 10+ nuclei revealed that Rgs12-overexpressing OCs were significantly larger as compared to empty vector-transfected controls ([Figure 2J](#fig2){ref-type="fig"}). To determine whether increased OC size translated to increased bone resorptive activity in our study, RAW264.7 cells were similarly cultured on calcium phosphate surfaces ([Figure 2K--L](#fig2){ref-type="fig"}). Consistent with our overall findings, ectopic overexpression of Rgs12 in OCs potently increased bone resorption activity. Our findings therefore demonstrate the importance of Rgs12 in promoting OC formation and activity, which is consistent with the osteopetrotic phenotype observed in the Rgs12-deficient mouse model.

![Rgs12 is essential for osteoclast differentiation and bone resorption.\
(**A**) Rgs12 protein and (**B**) mRNA expression in wild-type BMMs stimulated with M-CSF and RANKL for the indicated times. (**C**) TRAP-stained osteoclasts differentiated from BMMs isolated from Rgs12 cKO and control mice and the (**D**) number of TRAP-positive and multinucleated (≥3 nuclei) OCs were counted (N = 4). (**E--F**) Bone resorption activity of OCs derived from Rgs12 cKO and control BMMs cultured on calcium phosphate-coated plastic (N = 5). The light-colored areas correspond to areas resorbed by OCs was quantified and presented as values relative to the total area measured. (**G**) Immunoblot to verify Rgs12 overexpression in RAW264.7 cells transfected with a vector carrying a recombinant N-terminus FLAG-tagged Rgs12 gene (Flag-Rgs12). RAW264.7 cells transfected with the empty vector was used as a negative control. (**H**) TRAP-stained osteoclasts derived from RAW264.7 cells transfected with an empty vector or Flag-Rgs12 and the (**I**) number of TRAP-positive and multinucleated (≥3 nuclei) osteoclasts from vector- and Flag-Rgs12-transfected RAW264.7 cells (N = 3). (**J**) OC size was estimated by quantifying the surface area of OCs containing 10+ nuclei normalized to the number of OCs with 10+ nuclei (N = 3). (**K--L**) Bone resorption activity of OCs derived from RAW264.7 cells transfected with empty vector or Flag-Rgs12 (N = 5). All results are means ± SD. Student's *t* test was used in all cases except for [Figure 1A and B](#fig1){ref-type="fig"} wherein one-way ANOVA was used (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). TRAP, tartrate-resistant acid phosphatase.](elife-42951-fig2){#fig2}

Rgs12-deficient osteoclast precursors show an increased expression of Nrf2-dependent antioxidant proteins {#s2-3}
---------------------------------------------------------------------------------------------------------

To uncover the role of Rgs12 in OC differentiation, we employed the *IonStar* liquid chromatography tandem mass spectrometry (LC-MS/MS)-based quantitative proteomics strategy ([@bib45]) to profile the temporal dynamics in the global protein levels in Rgs12 cKO and control BMMs at 0, 1, 3, and 5 days of OC differentiation ([Figure 3](#fig3){ref-type="fig"}). Proteomics analysis identified 3714 quantifiable proteins that are present in all samples (no missing data), using a highly stringent identification criteria of ≥2 peptides per protein and 1% false discovery rate ([Figure 3A](#fig3){ref-type="fig"}). Within this dataset, we identified 83 and 61 unique proteins that were significantly up- and downregulated, respectively, in Rgs12 cKO OCs relative to control. Proteins were considered significantly altered if they exceeded the empirically-determined thresholds set at p\<0.05 and\>0.3 log~2~-transformed ratio ([Figure 3B](#fig3){ref-type="fig"}). Most of the protein expression changes in Rgs12-deficient cells were captured at 3 and 5 days of OC differentiation ([Figure 3A](#fig3){ref-type="fig"}). Interestingly, the proteomic disturbances as a result of Rgs12 deletion closely coincided with the pattern of endogenous Rgs12 protein expression during OC differentiation ([Figure 2A](#fig2){ref-type="fig"}). To determine the biological significance of these altered proteins, we performed gene ontology analysis to identify the canonical pathways involved ([Figure 3C](#fig3){ref-type="fig"}). Classically processes related to OC differentiation (e.g. 'NFAT Signaling', 'RANK Signaling in OCs', and 'Role of OCs in Rheumatoid Arthritis') were enriched at 3 and 5 days of OC differentiation. Closer inspection showed that OC marker proteins including metalloproteinase-9 (Mmp9), TRAP, ATPase H^+^ transporting V0 subunit D2 (Atp6v0d2), and integrin β3 (Itgb3) were significantly downregulated in Rgs12 cKO OCs ([Figure 3D](#fig3){ref-type="fig"}). Additionally, the analysis revealed several biological functions related to ROS homeostasis that were impacted by Rgs12 deletion (e.g. 'Production of ROS', 'Superoxide Radical Degradation', and NRF2-mediated Stress Response') ([Figure 3C](#fig3){ref-type="fig"}). Inspection of the proteins involved in these pathways showed a significant upregulation of numerous Nrf2-dependent antioxidant enzymes responsible attenuating oxidative stress, including: peroxiredoxin 1/4 (Prdx1/4), thioredoxin 1/2 (Trxr1), glutathione reductase (Gshr), and NAD(P)H dehydrogenase quinone 1 (Nqo1) ([Figure 3E](#fig3){ref-type="fig"}). Upstream regulator (transcription factor) analysis by the Ingenuity Pathway Analysis software function identified that the antioxidant enzymes upregulated in Rgs12 cKO OCs share the common upstream regulator Nrf2, a key transcription factor that regulates cellular redox balance through the expression of protective antioxidant and phase II detoxification proteins. ([@bib50]; [@bib19]). Although the upstream regulator analysis predicted an upregulation of Nrf2 activity, the transcription factor itself was not detected by our proteomics analysis. Proteins of typically low abundance such as cytokines, signal regulatory molecules, and transcription factors tend to be 'crowded out' during MS analysis by more highly abundant proteins such those proteins involved in glycolysis and purine metabolism, protein translation, and cytoskeletal components ([@bib6]). Nonetheless, our proteomics-based discovery tool allowed us to generate the hypothesis that Nrf2 is aberrantly activated by Rgs12 deletion, causing excessive clearance of ROS by antioxidant enzymes and in turn disrupting OC differentiation.

![Proteomics analysis identified an increased expression of Nrf2-dependent antioxidant proteins in Rgs12-deficient osteoclast precursors.\
(**A**) Venn diagram summarizing the distribution of proteins that were significantly altered in Rgs12 cKO BMMs as compared to control at 0, 1, 3, and 5 days of OC differentiation. (**B**) Volcano plots depicting protein expression changes in Rgs12 cKO BMMs as compared to control cells. Optimized cutoff thresholds for significantly altered proteins was set at 1.3 log~2~-transformed ratios and p-value\<0.05. Data are means ± SD. Student's t test was performed to compare Rgs12 cKO and control BMMs at each time point (N = 3). (**C**) Gene ontology (GO) enrichment analysis to identify canonical pathways corresponding to the significantly altered proteins. For visualization purposes, the color intensity in the heat map diagram indicates the significance of GO term enrichment, presented as --log10(P-value). Hierarchical clustering analysis was used to group GO terms based on the p-value of enrichment. (**D--E**) The expression of OC marker proteins and Nrf2-regulated antioxidant proteins in Rgs12 cKO versus control BMMs. Mmp9, metalloproteinase-9; Trap, tartrate-resistant acid phosphatase; Nfatc1, nuclear factor of activated T cells, cytoplasmic 1; Atp6v0d2, ATPase H+ transporting V0 subunit D2; Itgb3, integrin β3; Prdx, peroxiredoxin; Cata, catalase; Trxr, thioredoxin; Gshr, glutathione reductase; Nqo1, NAD(P)H dehydrogenase quinone 1.\
10.7554/eLife.42951.011Figure 3---source data 1.Proteomics data presented in [Figure 3](#fig3){ref-type="fig"}.Quantitative proteomics analysis of 3714 proteins in Rgs12 cKO versus control OCs at different time-points of differentiation. Statistical comparisons between groups were evaluated by Student's *t* test (N = 3, p\<0.05).\
10.7554/eLife.42951.009Figure 3---source data 2.Summary of proteins involved in energy metabolism including glycolysis, TCA cycle, and oxidative phosphorylation.Log2-transformed ratios in Rgs12 knockout versus wild-type BMMs at the indicated time-points of osteoclast differentiation. Blue shaded cells indicate p-values\<0.05, green indicates downregulated proteins, and red indicates upregulated proteins.](elife-42951-fig3){#fig3}

Deletion of Rgs12 elevated Nrf2/Keap1 expression and Nrf2 activity {#s2-4}
------------------------------------------------------------------

Based on our proteomics analysis, we hypothesized that Rgs12 is needed to suppress Nrf2 activity and facilitate the formation of ROS, which has been previously shown to play a critical role in OC differentiation ([@bib27]; [@bib22]). To test this hypothesis, we assessed Nrf2 activity and the expression of Nrf2 and Keap1 in Rgs12 cKO and control precursor cells ([Figure 4](#fig4){ref-type="fig"}). Western blotting of Nrf2 in day 3 OCs also showed increased levels of Nrf2 in Rgs12 cKO cells ([Figure 4A--B](#fig4){ref-type="fig"}). Keap1, however, which is known to suppresses Nrf2 activity by facilitating its degradation via the proteasome pathway, was unexpectedly elevated in Rgs12-deficient cells. Furthermore, immunofluorescence staining of Nrf2 demonstrated increased nuclear translocation of the transcription factor in Rgs12 cKO cells ([Figure 4C](#fig4){ref-type="fig"}, upper panel). The elimination of ROS with N-acetylcysteine (NAC), a precursor to the antioxidant glutathione, was able to completely suppress Nrf2 nuclear translocation in both Rgs12 cKO and control BMMs ([Figure 4C](#fig4){ref-type="fig"}, middle panel). Conversely, induction of oxidative stress using the peroxide *tert*-buthylhydroxyperoxide (tBHP) potently induced Nrf2 nuclear translocation ([Figure 4C](#fig4){ref-type="fig"}, bottom panel). To further test whether elevated Nrf2 activity in Rgs12-deficient OCs could result in reduced intracellular ROS levels, we detected intracellular ROS levels. As expected, the RANKL-dependent ROS induction observed in control cells was suppressed in Rgs12 cKO OCs ([Figure 4D](#fig4){ref-type="fig"}). These findings demonstrate an abnormal upregulation of Nrf2 activity and expression in Rgs12-deficient cells, indicating that Rgs12 may be required to suppress Nrf2 to facilitate osteoclastogenesis.

![Increased Nrf2 activation and expression of antioxidant proteins in Rgs12-deficient osteoclast precursors.\
(**A--B**) Immunoblot of Nrf2 and Keap1 protein levels in Rgs12 cKO and control BMMs treated with RANKL for 72 hr. Densitometry analysis was performed on bands and normalized to β-actin (N = 3, \*p\<0.05). (**C**) Nrf2 immunofluorescence staining in Rgs12 cKO and control BMMs differentiated with M-CSF and RANKL for 72 hr. As a negative control for Nrf2 nuclear translocation, cells were treated with the antioxidant compound NAC (5 mM, 16 hr) to suppress cellular ROS. Conversely, as a positive control for Nrf2 nuclear translocation, cells were treated with the peroxidase tBHP (50 μM, 16 hr) to induce oxidative stress. (**D**) Induction of ROS levels in Rgs12 cKO and control BMMs differentiated for 72 hr, kept in serum-free medium for 6 hr, and stimulated with RANKL for the indicated times. ROS levels were measured using the DCFDA fluorescence method. Data are means ± SD (N = 5, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). *DAPI, 4,6-diamidino-2-phenylindole; NAC, N acetylcysteine; tBHP, tert-butylhydroxyperoxide. ROS, reactive oxygen species. DCFDA, 2',7'-dichlorofluorescin diacetate. RFU, relative fluorescence units.*.](elife-42951-fig4){#fig4}

Rgs12-mediated suppression of Nrf2 activity is dependent on the proteasome degradation pathway {#s2-5}
----------------------------------------------------------------------------------------------

Under basal conditions (i.e. absence of cellular stress), Nrf2 remains inactive through its interaction with Keap1, which causes its continual ubiquitination and degradation via the proteasome pathway ([@bib49]; [@bib59]). A variety of stress conditions can induce conformational changes in Keap1, thereby releasing Nrf2 from the ubiquitin-proteasome pathway, allowing it to accumulate and translocate into the nucleus ([@bib20]; [@bib24]). To better understand the mechanism by which Rgs12 suppresses Nrf2 activity, we therefore first determined whether the ability of Rgs12 to suppress Nrf2 activity relies on this canonical mechanism ([Figure 5A](#fig5){ref-type="fig"}). Given that Rgs12 deletion resulted in elevated Nrf2 expression and nuclear translocation, we first determined whether Rgs12 overexpression could exert an opposite effect ([Figure 5A--B](#fig5){ref-type="fig"}). We measured Nrf2 protein levels in RAW264.7 cells stably transfected with the Rgs12-His or empty vector and found no difference when cells are at their un-induced, basal state. Stimulation of RAW264.7 cells with *tert*-buthylhydroquinone (tBHQ), which is known to directly bind Keap1 and attenuate its inhibitory effect on Nrf2 ([@bib1]), caused a robust induction of Nrf2 protein levels in a dose-dependent manner ([Figure 5A--B](#fig5){ref-type="fig"}). More importantly, RAW264.7 cells overexpressing Rgs12 showed a significant reduction of Nrf2 protein levels that resulted from Keap1 inhibition compared to those in the control cells. Moreover, the ability of Rgs12 to facilitate Nrf2 degradation despite the inhibition of Keap1 suggests that Rgs12 functions downstream of Keap1, either by controlling the ubiquitination or proteasomal degradation of Nrf2.

![Suppression of Nrf2 protein levels by Rgs12 is dependent on the proteasome degradation pathway.\
(**A**) Diagram summarizing the inhibitors of the Keap1-proteasome axis to modulate Nrf2 protein levels. (**B**) RAW264.7 cells stably-transfected with Rgs12-His or empty vector treated with increasing doses of tBHQ. (**C**) Nrf2 and Keap1 protein levels were quantified by densitometry analysis and normalized to β-actin (N = 3, \*p\<0.05, \*\*p\<0.01). (**D**) Western blot to detect Nrf2 and Keap1 in RAW264.7 cells stably-transfected with empty vector or Flag-Rgs12. RAW264.7 cells were treated with a combination of RANKL (100 ng/mL, 72 hr) and the proteasome inhibitor MG-132 (25 μM, 4 hr). (**E**) Nrf2 and Keap1 protein levels were quantified by densitometry analysis and normalized to β-actin (N = 3, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). (**F**) qPCR analysis of Nrf2 and Keap1 transcript levels in RAW264.7 cells transfected with Rgs12-His or empty vector. Data are means ± SD. Two-tailed *t* test was performed (N = 3, \*p\<0.05). tBHQ, *tert*-butylhydroquinone.](elife-42951-fig5){#fig5}

Given the possibility that the reduction of Nrf2 levels in Rgs12 overexpression cells may be a result of increased Nrf2 degradation, we further tested whether inhibiting the proteasome, a step downstream of Keap1, could attenuate the ability of Rgs12 to facilitate Nrf2 degradation ([Figure 5D and E](#fig5){ref-type="fig"}). Similar to tBHQ, preventing Nrf2 degradation using the proteasome inhibitor MG-132 caused Nrf2 protein to substantially accumulate ([Figure 5D](#fig5){ref-type="fig"}, left panel). Interestingly, when Nrf2 protein levels were artificially induced, we observed the presence of a lower molecular weight band, which could correspond to a different post-translational modification state (e.g. unphosphorylated or non-ubiquitinated). Furthermore, we did not observe any changes in Keap1 protein levels. In the previous scenario wherein Rgs12 overexpression could still promote Nrf2 degradation in spite of tBHQ treatment, this was not the case when using MG-132. In fact, inhibiting the proteasome was able to reverse the ability of Rgs12 to promote Nrf2 degradation, indicating the requirement for Rgs12 in the proteasome's function. We subsequently repeated this experiment in RAW264.7 cells differentiated for 3 days with RANKL ([Figure 5D](#fig5){ref-type="fig"}). Interestingly, RANKL treatment correlated with reduced Nrf2 levels in OCs ([Figure 5D](#fig5){ref-type="fig"}, right panel). Our observation corroborates with previous findings documenting the suppressive effect of RANKL on Nrf2 expression, which was attributed to reduced transcriptional activity ([@bib22]; [@bib17]). We confirmed this effect by measuring the *Nrf2* transcript levels by qPCR (Figure F). More importantly, we demonstrate that Rgs12 overexpression could suppress Nrf2 protein levels, but inhibition of the proteasome using MG-132 reversed this effect ([Figure 5D](#fig5){ref-type="fig"}, right panel). To confirm that Rgs12 inhibits Nrf2 through a post-translational mechanism, we measured Nrf2 transcript levels by qPCR and found no difference between vector control and Rgs12-overexpressing cells ([Figure 5F](#fig5){ref-type="fig"}). Overall, our data collectively indicate that Rgs12 suppresses Nrf2 activity by facilitating its degradation through the proteasome-dependent pathway.

Rgs12-mediated activation of osteoclast MAPK ERK1/2 and NFκB signaling is dependent on intracellular ROS {#s2-6}
--------------------------------------------------------------------------------------------------------

It was previously demonstrated that ROS could act as an intracellular signal mediator OC differentiation, and is required for the RANKL-dependent activation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and NFκB ([@bib27]; [@bib14]). Given our findings that Rgs12 could suppress the activity of Nrf2 and thereby promoting intracellular ROS, we hypothesized that Rgs12 could promote RANKL-dependent signaling, and that this effect would be abrogated by the addition of an antioxidant ([Figure 6A--B](#fig6){ref-type="fig"}). As expected, RAW264.7 cells overexpressing Rgs12 demonstrated a more robust activation of ERK1/2 and NFκB phosphorylation but not p38 MAPK. Pretreating Rgs12 overexpressing cells with the antioxidant NAC diminished ERK1/2 activation, and almost completely abrogated NFκB activation. These results support the role of Rgs12 in promoting ROS that is important OC signaling, likely through the suppression of Nrf2 activity.

![Rgs12-dependent activation of ERK1/2 and NFκB was suppressed by antioxidants.\
(**A**) Western blot detected phosphorylated or total p38, NFκB, and Erk1/2 in transfected RAW264.7 cells induced with RANKL (200 ng/mL) and M-CSF (100 ng/mL) for the indicated times. Cells were pretreated with NAC (5 mM, 4 hr) to suppress intracellular ROS. (**B**) Band density was quantified by ImageJ and phosphorylated and unphosphorylation/total protein levels were normalized to β-actin. Relative phosphorylation is presented as the ratio between the phosphorylated normalized to the nonphosphorylated/total protein. Two-tailed *t* tests were used to compare vector and Rgs12-His groups (N = 3, \*p\<0.05). (**C**) Model of the role of Rgs12 in suppressing Nrf2 to promote ROS and OC differentiation. M/R, M-CSF and RANKL. NAC, N-acetylcysteine.](elife-42951-fig6){#fig6}

Discussion {#s3}
==========

The importance of ROS in osteoclasts has been underlined by the growing corpus of evidence demonstrating that ROS increased with aging or during inflammation can stimulate bone resorption and exacerbate bone loss ([@bib8]). Targeting ROS in diseases of excess bone resorption such as osteoporosis could therefore represent a novel therapeutic strategy. An important mechanism of cellular ROS clearance relies on the Keap1-Nrf2 pathway, which has been well characterized especially in the context of cancer biology ([@bib21]); however, the upstream signaling molecules that could regulate the Keap1-Nrf2 axis in OCs remains unknown. Targeting this gap in knowledge, our study uncovered a novel role of the signaling protein Rgs12 in regulating Nrf2, thereby controlling cellular redox state and OC differentiation.

Within this study, we first demonstrated the essential role of Rgs12 in OC differentiation such that myeloid cell-targeted Rgs12 knockout mice exhibited an osteopetrotic phenotype, evidenced by reduced OC numbers but no changes to OB numbers nor bone formation ([Figure 1](#fig1){ref-type="fig"}). Furthermore, OC precursors isolated from these mice showed reduced in vitro OC differentiation and bone resorptive activity ([Figure 2](#fig2){ref-type="fig"}). On the contrary, forced overexpression of Rgs12 in RAW264.7 cells significantly promoted OC formation and increased the size of the resultant OCs, which was also associated with increased bone resorptive activity. However, the mechanism by which Rgs12 regulates OC differentiation remains unclear, to which we investigated more deeply using a leading-edge and high-throughput proteomics technique.

Proteomics is a powerful tool that has led to numerous discoveries of proteins and biological processes that drive OC differentiation ([@bib43]). Notably, this technique was recently used to map the podosome proteome which helped to advance our understanding of determinants in the macrophage multinucleation process ([@bib39]; [@bib9]), and how metabolism and energy is redirected towards bone resorption in OCs ([@bib4]). Proteomics can therefore provide a broad yet informative overview of the systemic changes in the differentiating OC. To discover the cellular function of Rgs12 in OCs, we employed a robust and high-throughput quantitative proteomics approach to characterize the global protein changes of OCs derived from Rgs12 cKO and cKO BMMs ([Figure 3](#fig3){ref-type="fig"}). The analysis revealed that most perturbations to the proteome was related to day 3 and 5 of OC differentiation, which coincides with the timing of Rgs12 upregulation in wild-type OCs ([Figure 2A--B](#fig2){ref-type="fig"}). This overlap suggests that Rgs12 may be more important to later phases of OC differentiation, including cell-cell fusion and bone resorption. The analysis also identified the upregulation of a collection of antioxidant enzymes that are all transcriptionally regulated by the antioxidant response element (ARE) within the promoter region, which is activated by the transcription factor Nrf2 ([@bib38]). While the upregulation of these genes would lead one to surmise that Nrf2 should be similarly increased, the transcription factor was not detected in the proteomics analysis, which is likely result of technical limitations inherent to current LC-MS capabilities. It was previously reported that transcription factor protein levels are notoriously difficult to obtain due to many having relatively low expression levels that are generally below current mass spectrometer detection limits ([@bib46]). The quantitation of transcription factors typically entails an upstream enrichment/separation step before LC-MS analysis. Therefore, the absence of Nrf2 in our proteomics analysis is not an unusual happenstance from a technical standpoint. Alternatively, we confirmed our proteomics findings by showing increased Nrf2 protein levels and nuclear translocation activity in Rgs12-deficient osteoclasts ([Figure 4A--C](#fig4){ref-type="fig"}).

Based on our preliminary evidence, we further investigated the role of Rgs12 in Nrf2 signaling and found that Nrf2 protein levels and nuclear translocation were increased in OC precursors in which Rgs12 was depleted ([Figure 4](#fig4){ref-type="fig"}). Because our data showed that Rgs12 deficiency upregulated Nrf2, we expected that Keap1 levels should be reduced in order to facilitate the increased Nrf2 activity. On the contrary, Keap1 levels were upregulated in Rgs12-deficient cells, to which we speculate that Rgs12-deficient cells may be overcompensating Keap1 expression in order to rein back the increased Nrf2 activity. Nevertheless, consistent with the upregulation of Nrf2 and its corresponding antioxidant enzymes, the RANKL-dependent induction of ROS was attenuated in Rgs12-deficient cells. Through an orthogonal approach, we demonstrated that Rgs12 overexpression in OC precursors could also enhance RANKL-mediated activation of ERK1/2 and NFκB ([Figure 6](#fig6){ref-type="fig"}), which are established to be dependent on ROS ([@bib17]). Furthermore, inhibition of intracellular ROS blocked the effect of Rgs12 overexpression, indicating that Rgs12 promotes RANKL-dependent signaling by facilitating ROS production. Overall, the data collectively demonstrate that Rgs12 promotes osteoclastogenesis by facilitating ROS generation through the suppression of Nrf2 and its target antioxidant genes.

The transcription factor Nrf2 is constitutively expressed but its activity is inhibited through its interaction with Keap1. Under basal conditions, Nrf2 is restricted to the cytoplasm where it is continually depleted through the proteosomal degradation pathway. When bound to Nrf2, Keap1 recruits the cullin 3 (Cul3)-dependent E3 ubiquitin ligase complex, which ubiquitinates and targets Nrf2 for degradation by the 26S proteasome ([@bib59]; [@bib20]; [@bib37]; [@bib33]). Keap1 protein contains multiple reactive cysteine residues that serve as redox sensors ([@bib1]) that are sensitive to stressor conditions including oxidative stress causes the electrophilic modification of Keap1, inducing conformational changes, causing the protein to dissociate from Nrf2 and thereby allowing the transcription factor to enter the nucleus ([@bib49]). We therefore determined how Rgs12 regulates this well-defined mechanism ([Figure 5](#fig5){ref-type="fig"}). tBHQ is a selective inhibitor of Keap1 activity by covalently binding the protein's reactive thiols and as a result activate Nrf2 and its downstream proteins in RAW264.7 cells ([@bib1]). tBHQ was also previously shown to inhibit OC differentiation via the upregulation of heme oxygenase-1, a Nrf2-dependent antioxidant enzyme ([@bib53]). In this study, we determined whether Rgs12 could suppress the tBHQ-dependent upregulation of Nrf2 ([Figure 5B](#fig5){ref-type="fig"}). We reasoned that if Rgs12 relies on a Keap1-dependent mechanism, then the inhibition of Keap1 by tBHQ should prevent the ability of Rgs12 to suppress Nrf2. However, we observed that Rgs12 was still able to suppress Nrf2 despite the pharmacological blockade of Keap1 activity, thereby indicating that Rgs12 functions downstream of Keap1.

Following Keap1-mediated ubiquitination of Nrf2, the targeted protein should be degraded by the proteasome. Again, we reasoned that if Rgs12 is dependent on the proteasomal degradation pathway, then inhibition of this pathway using the proteasome inhibitor MG-132 should prevent Rgs12-mediated suppression of Nrf2. Indeed, we found that Inhibiting the proteasome was able to reverse the Rgs12-mediated degradation of Nrf2, which places Rgs12 in between Keap1 and the proteasome in the Nrf2 degradation pathway ([Figure 5D--E](#fig5){ref-type="fig"}). Thus, Rgs12 could either regulate the Cul3-dependent E3 ubiquitin ligase complex to facilitate the ubiquitination of Nrf2, or directly control proteasome activity. While Keap1 certainly plays a canonical role in Nrf2 suppression, the evidence herein suggest that Keap1 is not involved in the Rgs12 function.

It is also interesting to note that NFκB activation is also dependent on the proteasomal degradation of inhibitor of κB (IκB), which otherwise sequesters NFκB to the cytoplasm ([@bib7]). If Rgs12 could modulate proteasome activity, it is possible that Rgs12 could directly promote NFκB by facilitating the degradation of IκB. However, the fact that antioxidant treatment to suppress ROS could almost completely block the phosphorylation of NFκB points to an important involvement of ROS, and not just simply the proteasomal degradation of IκB in NFκB activation ([Figure 6](#fig6){ref-type="fig"}). Nonetheless, this potential crosstalk between the NFκB and Nrf2 pathways will need to be evaluated in future studies.

ROS is an inevitable byproduct of the mitochondrial electron transport chain (oxidative phosphorylation, OXPHOS) during ATP synthesis. Microscopy analyses have noted the high abundance of mitochondria in osteoclasts as early as 1961 ([@bib12]), but interest in the metabolic profile that supports OC differentiation has made a resurgence in recent years. As examples, we and others through the proteomic study of OCs have reported that proteins involved in ATP synthesis were elevated in mature osteoclasts as compared to precursors ([@bib4]; [@bib36]). Additionally, it was demonstrated that mature OCs exhibit larger mitochondria, higher levels of enzymes of the electron transport chain, and higher oxygen consumption rates ([@bib29]). The evidence collectively point towards OXPHOS as a main bioenergetic source for osteoclast differentiation, and can therefore be considered an integral aspect of the process. As a consequence of increased mitochondrial biogenesis, ROS would similarly be elevated due to the 'leakiness' of the electron transport chain, which in turn contributes to the ROS that promotes OC differentiation. As such, an increase in ROS has been associated with mitochondria biogenesis in osteoclasts ([@bib18]), and mitochondrial ROS is essential for osteoclast formation ([@bib5]). Therefore, the analysis of OXPHOS and glycolytic patterns should not be discounted in a study that focuses on redox biology. To address this concern, we evaluated the molecular subsets in the proteome involved in the energy metabolism pathways including glycolysis, tricarboxylic acid (TCA) cycle, and OXPHOS pathways ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}).

The loss of Rgs12 in BMMs led to the inhibition of RANKL-dependent ROS, which we demonstrated was a function of increased Nrf2 activity and elevated levels of its target antioxidant enzymes. At the same time, the proteomics analysis identified a reduction of proteins involved in the TCA cycle and OXPHOS ([Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Interestingly, cytochrome b5 type A (CYB5A) was against the general trend and was significantly increased by \~30% in Rgs12-deficient BMMs. The TCA cycle is responsible for the consumption of acetyl-CoA to generate NADH which is fed into the OXPHOS pathway to power ATP synthase and catalyze the formation of ATP. The impediment of OXPHOS, which requires molecular oxygen as co-factor, can shift ATP production towards anaerobic glycolysis under hypoxic and other conditions. However, the proteomic analysis revealed that protein levels of phosphofructokinase (PFK), the rate-limiting enzyme of glycolysis, were unaffected by Rgs12 deletion ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). In fact, all enzymes we detected that are involved in the glycolytic pathway with the exception of enolase 3 (a.k.a. phosphopyruvate hydratase) were unaffected by the loss of Rgs12.

On one hand, the loss of Rgs12 was associated with reduced OXPHOS, which would theoretically contribute to lower ROS levels. Conversely, the inhibition of OC differentiation could lead to reduced mitochondrial biogenesis, which could also explain lowered ROS levels in Rgs12-deficient BMMs. Therefore, mitochondrial ROS could be a contributing factor in Rgs12 function---albeit likely as a secondary effect. Although OXPHOS enzymes were reduced in Rgs12-deficient osteoclasts, only 19/83 proteins identified (22.9%) were altered, as compared to 26/26 proteins (100%) identified as Nrf2 targets ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Additionally, the magnitude of protein expression fold-changes was markedly higher in Nrf2 response genes as compared to OXPHOS genes. Therefore, the higher degree of intra-group concordance and magnitude of expression of Nrf2 genes both indicate a more targeted response, whereas the weak pattern of expression of OXPHOS genes suggests an equivocal effect. Secondly, Nrf2 antioxidant proteins act downstream of mitochondrial ROS formation by acting directly on ROS. This effect is best exemplified by the fact that the ectopic expression of mitochondria-targeted catalase was able to suppress ROS and inhibit OC differentiation ([@bib5]). In the case of Rgs12 overexpression, it could be expected that increased mitochondrial ROS production would also need the concomitant suppression of Nrf2 to raise the overall intracellular ROS level. In the current work, we demonstrate that Rgs12 could promote Nrf2 degradation. Therefore, the inhibition of RANKL-dependent ROS associated with loss of Rgs12 was unlikely to be the direct result of glycolytic shift or reduced OXPHOS. While changes in mitochondrial ROS could be an minor aspect of Rgs12 function, but Nrf2 remains an essential component in the overall scheme.

In conclusion, we identified a new gene that could modulate the Nrf2-proteasome axis, which forms the crux of redox homeostasis in many biological contexts. Our study also points to a novel role of Rgs12 in OC redox biology, thus forming the molecular basis for developing therapies to modulate ROS for osteoporosis and other diseases of bone loss. Outside of its role in bone homeostasis, Rgs12 has also been shown to hold diverse and significant roles in other clinical contexts including pathological cardiac hypertrophy ([@bib16]), tumor suppression in African American prostate cancer ([@bib51]), and psychostimulant-induced increases in dopamine levels in the brain ([@bib13]). We speculate that the ability of Rgs12 to regulate Nrf2 could be an important clue to better understand the role of Rgs12 in the context of cardiac disease and tumorigenesis, in which ROS is known to have significant implications. Therefore, our research would have widespread appeal to audiences of different research backgrounds.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                           Designation                                                              Source or\                                                             Identifiers                                                     Additional\
  (species) or\                                                                                                    reference                                                                                                                              information
  resource                                                                                                                                                                                                                                                
  --------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Genetic reagent (*M. musculus*)         *Rgs12^flox/flox^*                                                       [@bib54]                                                                                                                               

  Genetic reagent (*M. musculus*)         *LyzM^Cre^*                                                              Jackson Laboratory                                                     Stock \#: 018956                                                

  Genetic reagent (*M. musculus*)         *Rgs12* cDNA                                                             This paper                                                             NCBI: NM_173402.2                                               

  Cell line (*M. musculus*)               RAW264.7                                                                 American Type Culture Collection                                       Cat. \#: TIB-71                                                 

  Cell line (*M. musculus*)               CMG14-12                                                                 PMID: [10934646](https://www.ncbi.nlm.nih.gov/pubmed/?term=10934646)                                                                   Dr. Sunao Takeshita (Nagoya City University, Nagoya, Japan)\
                                                                                                                                                                                                                                                          Cell line used to produce M-CSF-containing supernatant.

  Cell line (*E. coli*)                   Modified Origami B(DE3)                                                  [@bib30]                                                                                                                               Dr. Ding Xu (University at Buffalo, Buffalo, NY, USA). Modified bacterial cell line co-expresses chaperone proteins.

  Transfected construct (synthesized)     p3XFLAG-myc-CMV-26                                                       Sigma-Aldrich                                                          Cat. \#: E7283                                                  

  Transfected construct (synthesized)     p3XFLAG-myc-CMV-26-Rgs12                                                 This paper                                                                                                                             See Methods for details.

  Transfected construct (synthesized)     pcDNA3.1(+)-c-His                                                        Genscript                                                                                                                              Custom vector available through Genscript's cloning services.

  Transfected construct (synthesized)     pcDNA3.1(+)-Rgs12-c-His                                                  This paper                                                                                                                             See Methods for details.

  Recombinant DNA reagent (synthesized)   mRANKL-His (K158-D316)                                                   Other                                                                                                                                  Dr. Ding Xu (University at Buffalo, Buffalo, NY, USA).

  Sequence-based reagent                  Primers                                                                  Integrated DNA Technologies                                                                                                            Primer sequences detailed in Methods.

  Peptide, recombinant protein            M-CSF                                                                    R and D Systems                                                        Cat. \#: 416 ML-010                                             

  Commercial assay or kit                 Acid Phosphatase, Leukocyte (TRAP) Kit                                   Sigma-Aldrich                                                          Cat. \#: 387A-1KT                                               

  Commercial assay or kit                 SimpleSeq DNA Sequencing                                                 Eurofins Genomics                                                                                                                      

  Commercial assay or kit                 Pierce High Capacity Endotoxin Removal Resin                             Thermo Fisher Scientific                                               Cat. \#: 88270                                                  

  Commercial assay or kit                 Osteo Assay Surface                                                      Corning                                                                Cat. \#: 3987                                                   

  Commercial assay or kit                 TRIzol Reagent                                                           Invitrogen                                                             Cat. \#: 15596026                                               

  Commercial assay or kit                 RNA to cDNA EcoDry Premix                                                Clontech                                                               Cat. \#: 639549                                                 

  Commercial assay or kit                 2x SYBR Green qPCR Master Mix                                            Bimake                                                                 Cat. \#: B21203                                                 

  Commercial assay or kit                 Rac1 Pulldown Activation Assay Kit                                       Cytoskeleton                                                           Cat. \#: BK035-S                                                

  Chemical compound, drug                 Calcein                                                                  Sigma-Aldrich                                                          Cat. \#: C0875                                                  

  Chemical compound, drug                 FuGENE HD Transfection Reagent                                           Promega                                                                Cat. \#: E2311                                                  

  Chemical compound, drug                 Geneticin (G418)                                                         Thermo Fisher Scientific                                               Cat. \#: 10131035                                               

  Chemical compound, drug                 DCFDA                                                                    Sigma-Aldrich                                                          Cat. \#: D6883                                                  

  Chemical compound, drug                 Phenol red-free MEM                                                      Gibco/Thermo Fisher                                                    Cat. \#: 51200038                                               

  Chemical compound, drug                 cOmplete, Mini, EDTA-free                                                Roche/Thermo Fisher                                                    Cat. \#: 5892791001                                             

  Chemical compound, drug                 Image-iT FX signal enhancer                                              Thermo Fisher Scientific                                               Cat. \#: I36933                                                 

  Chemical compound, drug                 DAPI                                                                     Thermo Fisher Scientific                                               Cat. \#: D1306                                                  

  Chemical compound, drug                 ProLong Gold Antifade Mountant                                           Thermo Fisher Scientific                                               Cat. \#: P36930                                                 

  Chemical compound, drug                 tBHP                                                                     Sigma-Aldrich                                                          Cat. \#: B2633                                                  

  Chemical compound, drug                 MG-132                                                                   Selleck Chemicals                                                      Cat. \#: S2619                                                  

  Chemical compound, drug                 NAC                                                                      Sigma-Aldrich                                                          Cat. \#: A9165                                                  

  Chemical compound, drug                 tBHQ                                                                     Sigma-Aldrich                                                          Cat. \#: 112941                                                 

  Antibody                                Nrf2 (H-300), rabbit polyclonal                                          Santa Cruz Biotechnology                                               Cat. \#: sc-13032                                               ICC (1:10), WB (1:100)

  Antibody                                Nrf2 (C-20), rabbit polyclonal                                           Santa Cruz Biotechnology                                               Cat. \#: sc-722                                                 WB (1:100)

  Antibody                                Keap1 (E-20), goat polyclonal                                            Santa Cruz Biotechnology                                               Cat. \#: sc-15246                                               WB (1:100)

  Antibody                                Phospho-p38 (Thr180/Tyr182), rabbit polyclonal                           Cell Signaling Technology                                              Cat. \#: 9211                                                   WB (1:1000)

  Antibody                                p38, rabbit polyclonal                                                   Cell Signaling Technology                                              Cat. \#: 9212                                                   WB (1:1000)

  Antibody                                Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb   Cell Signaling Technology                                              Cat. \#: 4370S                                                  WB (1:1000)

  Antibody                                ERK1/2, rabbit polyclonal                                                Cell Signaling Technology                                              Cat. \#: 9102                                                   WB (1:1000)

  Antibody                                Phospho-NFκB p65 (Ser536), rabbit monoclonal                             Cell Signaling Technology                                              Cat. \#: 3033                                                   WB (1:1000)

  Antibody                                NFκB p65, rabbit polyclonal                                              Cell Signaling Technology                                              Cat. \#: 3034                                                   WB (1:1000)

  Antibody                                β-actin, mouse monoclonal                                                Santa Cruz Biotechnology                                               Cat. \#: sc-47778                                               WB (1:4000)

  Software, algorithm                     OsteoMeasure                                                             OsteoMetrics                                                                                                                           

  Software, algorithm                     ImageJ                                                                   NIH                                                                    RRID: [SCR_003070](https://scicrunch.org/resolver/SCR_003070)   

  Software, algorithm                     Primer-BLAST                                                             NIH                                                                                                                                    

  Software, algorithm                     CFX Maestro                                                              Bio-Rad                                                                                                                                

  Software, algorithm                     IonStar                                                                  [@bib45];\                                                                                                                             
                                                                                                                   [@bib44]                                                                                                                               

  Software, algorithm                     Ingenuity Pathway Analysis                                               Qiagen                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Generation of Rgs12 conditional knockout mice {#s4-1}
---------------------------------------------

*Rgs12^flox/flox^* mice were crossed with *LyzM^Cre^* transgenic mice to generate Rgs12 cKO mice specific to the myeloid lineage in a C57BL/6J background. The methodology for generating *Rgs12^flox/flox^* and *LyzM^Cre^* mice and genotyping are previously described ([@bib10]; [@bib54]; [@bib57]). Mice used for experiments were 10--12 weeks old, as indicated. All animal studies were approved by the University at Buffalo and University of Pennsylvania Institutional Animal Care and Use Committees (IACUC).

Quantitative Micro-CT measurements {#s4-2}
----------------------------------

Quantitative analysis of bone morphology and microarchitecture was performed using a micro-CT system (USDA Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA). Fixed femur from 10-week-old Rgs12 cKO and control mice were analyzed and 3D reconstruction was used to determine bone volume to tissue volume (BV/TV), structure model index (SMI), trabecular thickness (Tb.Th, μm), trabecular number (Tb.N,/mm), and trabecular separation (Tb.Sp, μm).

Bone histology analysis {#s4-3}
-----------------------

Mouse tibiae and femurs from 10-week-old mice were excised and fixed in 4% PFA for 24 hr and decalcified in a 10% EDTA for 3--4 weeks at 4°C. The samples were embedded in paraffin, sectioned at 8 μm, stained with hematoxylin and eosin (H and E) or tartrate-resistant acid phosphatase (TRAP) using the Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich, St. Louis, MO, USA), and imaged using a Leica inverted microscope (DMI6000B, Leica, Germany).

Dynamic histomorphometry {#s4-4}
------------------------

To assess the rate of bone formation, mice were intraperitoneally injected with calcein (25 mg/kg) twice at postnatal day 90 and day 96. Mice were euthanized and harvested 2 days after last injection. Femurs were dissected and fixed in 4% PFA for 24 hr, dehydrated in ethanol, and embedded in optimal cutting temperature (OCT) compound for cryosection without decalcification. By applying Cryofilm tape (Section Lab, Hiroshima, Japan), 8 μm longitudinal sections were cut from distal femurs using a microtome (CM1950, Leica, Germany). Measurements of surface-based histomorphometric indices were performed using the OsteoMeasure analysis system (OsteoMetrics, Decatur, GA). These indices were used to calculate bone formation rate per bone surface (BFR/BS, μm^3^/um^−2^ per day), mineral apposition rate (MAR, μm per day), OB number per bone perimeter (N.Ob/B.Pm, mm^−1^) and OC number per bone perimeter (N.Oc/B.Pm, mm^−1^) as previously described ([@bib58]; [@bib32]).

Generation of Rgs12 expression vectors {#s4-5}
--------------------------------------

Full length *Rgs12* (Accession: NM_173402.2) cDNA was cloned into the p3XFLAG-myc-CMV-26 expression vector (Sigma-Aldrich, St. Louis, MO, USA). Briefly, *Hind*III sites were incorporated into both termini of the *Rgs12* cDNA using restriction-site-generating PCR, and the restriction sites were used to insert the Rgs12 sequence into the expression vector containing an N-terminus FLAG tag sequence (Flag-Rgs12). The primer walking method was used to validate the correct directionality of the insert. Additionally, a vector expressing C-terminus His-tagged Rgs12 (Rgs12-His) was generated by subcloning the *Rgs12* cDNA into the pcDNA3.1(+)-c-His vector (Genscript, Piscataway, NJ, USA). *Hind*III and *Eco*RV sites were introduced by PCR and the restriction sites were used to insert *Rgs12* into the pcDNA3.1(+)-c-His vector. All vector constructs were confirmed by DNA sequencing (Eurofins Genomics, Louisville, KY, USA).

Stable transfection {#s4-6}
-------------------

RAW264.7 cells were purchased from ATCC which was confirmed to be free of mycoplasma contamination. RAW264.7 cells were seeded at 2 × 10^6^ cells per 6-well and transfected using FuGENE HD reagent (Promega, Madison, WI, USA) according to manufacturer's instructions at a 1:3 DNA to transfection reagent ratio. After 48 hr post-transfection, cells were treated with 0.4 mg/mL geneticin (G418, Thermo Fisher Scientific, Waltham, MA, USA) for 2 weeks until antibiotic-resistant colonies are formed. Stably transfected cells were thereafter maintained in media containing 0.4 mg/mL G418.

In vitro osteoclastogenesis and bone resorption assays {#s4-7}
------------------------------------------------------

The vector encoding the recombinant mRANKL-His (K158-D316) construct and a modified *E. coli* strain Origami B(DE3) cells (EMD Millipore, Billercica, MA, USA) co-expressing chaperone proteins that was used to express the recombinant RANKL were generous gifts from Dr. Ding Xu at the University at Buffalo. The protocol for expressing and purifying mRANKL-His was described previously ([@bib30]). Endotoxins were removed using the Pierce High Capacity Endotoxin Removal Resin (Thermo Fisher Scientific, Waltham, MA, USA).

BMMs were obtained from the tibiae and femurs of 10-week-old mice as described previously ([@bib55]). For in vitro osteoclastogenesis experiments, BMMs were seeded at 2 × 10^6^ cells per 24-well plates and stimulated with 100 ng/mL RANKL and 20 ng/mL M-CSF (R and D Systems, Minneapolis, MN, USA) for 5 days to generate mature OCs. RAW264.7 cells were seeded at 1.35 × 10^4^ cells per 24-well and stimulated with M-CSF and RANKL for 5 days. Prior to fixing and staining, RAW264.7-derived OCs were gently but thoroughly rinsed with PBS to remove mononuclear cells that tend to obscure OCs during imaging. TRAP staining was performed using the Acid Phosphatase, Leukocyte (TRAP) kit (Sigma-Aldrich, St. Louis, MO, USA). Cells were imaged using the Cytation 5 Cell Imaging Multi-Mode Reader (BioTek, Winooski, VT, USA) using the montage function. Osteoclasts were quantified by counting the number of TRAP^+^, multinucleated cells (MNCs,≥3 nuclei/cell) per well. Average osteoclast area was determined by measuring total TRAP^+^ area using the ImageJ software (US National Institute of Health, Bethesda, MA, USA) and dividing the value by total osteoclast number.

For bone resorptive activity experiments, the method above was applied except that cells were seeded on Osteo Assay Surface plates (Corning, Corning, NY) and allowed to differentiate and resorb the calcium phosphate surface for 5--6 days. A 10% bleach solution was added to each well for 5 min to remove cells, followed by rinsing with deionized water, and air-dried. Resorption pits were visualized and captured under a light microscope (DMI6000B, Leica, Germany) and analyzed using ImageJ software as previously described ([@bib31]).

Reverse transcription and quantitative PCR {#s4-8}
------------------------------------------

Total RNA was isolated from cultured BMMs and OCs using Trizol reagent (Invitrogen, Carlsbad, CA, USA) following manufacturer's instructions. cDNA was reverse transcribed from 2 μg total RNA using the RNA to cDNA EcoDry Premix kit (Clontech, Palo Alto, CA, USA). Primers were designed using Primer-BLAST ([@bib56]) and obtained from IDT (Integrated DNA Technologies, San Diego, CA, USA). Rgs12 (F: 5'-AAGATCCATTCCCTAGTGACC-3', R: 5'-ACCTCCACTTTCCCACCCTG-3', 587 bp), Nrf2 (F: 5'-GCCCACATTCCCAAACAAGAT-3', R: 5'-CCAGAGAGCTATTGAGGGACTG-3', 172 bp), Keap1 (F: 5'-TGCCCCTGTGGTCAAAGTG-3', R: 5'-GGTTCGGTTACCGTCCTGC-3', 104 bp), β-actin (F: 5'-CTAGGCACCAGGGTGTGAT-3', R: 5'-TGCCAGATCTTCTCCATG TC-3', 148 bp), GAPDH (F: 5'-AGGTCGGTGTGAACGGATTTG-3', R: 5'-TGTAGACCATGTAGTTGAGGTCA-3', 123 bp). qPCR was performed using the 2x SYBR Green qPCR Master Mix following manufacturer's instructions (Bimake, Houston, TX, USA). All reactions were performed in triplicate and normalized to the housekeeping gene β-actin or GAPDH as indicated. Data analysis was performed using the CFX Maestro software (Bio-Rad, Hercules, CA, USA).

Rac1-GTP immunoprecipitation {#s4-9}
----------------------------

The Rac1-GTP pulldown assay was performed following manufacturer instructions in the Rac1 activation assay kit (Cytoskeleton, Denver, CO, USA).

ROS measurement {#s4-10}
---------------

To measure ROS production, BMMs were seeded into black, glass-bottom 96-well plates and cultured with M-CSF for 48 hr until confluence. Cells were loaded with 20 μM 2'7'-dichlorofluorescein diacetate (DCFDA, Sigma) at 37°C for 30 min and washed using PBS. The cells were swapped into complete phenol red-free MEM (Gibco) containing RANKL/M-CSF. Fluorescence intensity was measured using the Cytation five plate reader (BioTek) with excitation wavelength at 488 nm and emission wavelength at 535 nm. Background signals (cells not loaded with DCF-DA) were subtracted. Experiments were carried out in quintuplicate wells.

Protein extraction and precipitation/On Pellet Digestion {#s4-11}
--------------------------------------------------------

Cells were harvested using ice-cold lysis buffer (50 mM Tris-formic acid, 150 mM NaCl, 0.5% sodium deoxycholate, 1% SDS, 2% NP-40, pH 8.0) with protease inhibitor (cOmplete, Mini, EDTA-free; Roche, Mannheim, Germany). Samples were prepared for MS analysis using an established method ([@bib45]; [@bib44]).

Liquid Chromatography-Tandem mass spectrometry analysis {#s4-12}
-------------------------------------------------------

The 'IonStar' LC-MS experimental pipeline was developed and optimized in a previous study ([@bib45]; [@bib44]). A stringent set of criteria including a low peptide and protein false discovery rate (FDR) of \<1% and≥2 peptides per protein was used for protein identification. An ion current-based quantification method (IonStar processing pipeline) was described previously ([@bib45]; [@bib44]).

Bioinformatics analysis {#s4-13}
-----------------------

Ingenuity Pathway Analysis (Qiagen, Redwood City, CA, USA) was used to perform gene ontology enrichment analysis. Hierarchical clustering analysis and heat map visualizations were performed using the *agnes* function in R Package *cluster* and *ggplot2* with the *viridis* color palette, respectively.

Immunofluorescence {#s4-14}
------------------

For the Nrf2 nuclear translocation experiment, BMMs were cultured on coverslips and treated with RANKL and M-CSF for 72 hr, 5 mM NAC for 16 hr, or 50 μM tBHP for 16 hr. Coverslips were fixed with 4% paraformaldehyde solution in PBS for 10 min at room temperature and permeabilized using 0.1% Triton X-100 for 5 min at room temperature. Coverslips were blocked using Image-iT FX signal enhancer (Thermo Fisher Scientific) for 1 hr at room temperature, stained with the primary antibody in 1% BSA/TBST overnight at 4°C, and stained with the secondary antibody for 1 hr at room temperature. 4,6-diamidino-2-phenylindole (DAPI) (Sigma) was used as a counterstain for nuclei. The coverslips were mounted using ProLong Gold antifade mountant (Thermo) and images were obtained using a fluorescence microscope (Leica, Wetzlar, Germany).

Western blotting {#s4-15}
----------------

For experiments studying the Keap1-Nrf2 pathway, cells were cultured in 6-well plates and pre-treated with the indicated concentrations of tBHQ or 25 µM MG-132 for 4 hr. For MAPK and NFκB activation experiments, stable-transfected RAW264.7 cells were cultured in 6-well plates and starved in serum-free medium containing 5 mM NAC for 16 hr. Cells were subsequently induced with RANKL (200 ng/mL) and M-CSF (100 ng/mL) for the indicated times. Western blotting was performed as described previously ([@bib58]). The primary antibodies used in this study were as follows: Nrf2 (H-300) and Nrf2 (C-20) (1:100, Santa Cruz Biotechnology, Dallas, TX, USA), Keap1 (E-20) (1:100, SCBT), phospho-p38 (Thr180/Tyr182) (1:1000, Cell Signaling Technology), p38 (1:1000, CST), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:1000, CST), ERK1/2 (1:1000, CST), phospho-NFκB p65 (Ser536) (1:1000, CST), NFκB p65 (1:1000, CST), and β-actin (1:4000, SCBT). Densitomety analysis was performed using ImageJ ([@bib42]) and normalized to the β-actin signal. Relative phosphorylation of was presented as the ratio between the phosphorylated normalized to the non-phosphorylated/total protein. NAC, tBHQ, and tBHP were obtained from Sigma-Aldrich (St. Louis, MO, USA), and MG-132 was obtained from Selleck Chemicals (Houston, TX, USA).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"Rgs12 enhances osteoclastogenesis by suppressing Nrf2 activity and promoting the formation of reactive oxygen species\" for peer review at *eLife*. Your article is being evaluated by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation is being overseen by Marianne Bronner as the Senior Editor.

Given the list of essential revisions, including new experiments, the editors and reviewers invite you to respond within the next two weeks with an action plan and timetable for the completion of the additional work. We plan to share your responses with the reviewers and then issue a binding recommendation.

Summary:

All three reviewers agree that demonstration of Rgs12 deletion led to increased bone mass and its overexpression increased OC number and size were novel observations. The proteomic analysis of Rgs12-deficient OCs identified novel peptides and upregulation of antioxidant enzymes under the transcriptional regulation of Nrf2 and is another strong component of the manuscript. Conversely, by showing that Rgs12 overexpression suppressed Nrf2 through a mechanism dependent on the 26S proteasome and promoted RANKL-induced phosphorylation of ERK1/2 and NFκB, a putative mechanism for the in vivo effects has been provided.

Nevertheless, there were four major concerns that need to be addressed.

Essential revisions:

First, the authors need to demonstrate in vitro functional activities of the osteoclast including resorption on dentin; this would further strengthen their argument of a major osteoclast defect as the cause of high bone mass with Rgs12 deletion.

Second, dynamic histomorphometry from tibia/femur and or vertebrae is essential to support the in vivo mechanisms proposed in the paper.

Third, further in vitro studies are needed in order to determine the differential response of bone marrow cells to mCSF and RANKL for levels of Rgs12 mRNA and protein compared to cultures treated with M-CSF alone.

Finally, no experiments were performed to test whether the altered Nrf2 levels cause the phenotype induced by Rgs12 deletion: these need to be done.

In addition, some consideration should be included about the effects of excess ROS on the metabolic program of the osteoclast.

*Reviewer \#1:*

This manuscript reports that deletion of Rgs12 in vivo increased bone mass and in vitro decreased osteoclastogenesis and ROS production and increased Nrf2 protein level and Nrf2-dependent antioxidant enzymes.

1\) The major conclusion of the paper, that Rgs12 deletion decreases osteoclast formation, needs to be tested in vivo by reporting quantitation of osteoclast and osteoblast numbers and activity in the histology shown in Figure 1C. The in vivo data also lacks an important control (LysM-cre;Rgs12+/+ mice) because cre expression can cause effects on bone phenotype even without the presence of a floxxed allele. The in vitro data also needs to be strengthened by measuring osteoclast activity (pit formation) rather than relying on osteoclast number and size.

2\) The effects of Rgs12 deletion and overexpression on Rgs12 protein levels appear to be quite modest and not observable in the western blots, and their quantitation by densitometry is unlikely to be sensitive enough to reliably detect the small differences, which, even if true, are unlikely to be sufficient to have a major effect on the cellular phenotype. Moreover, no experiments were performed to test whether the altered Nrf2 levels cause the phenotype induced by Rgs12 deletion.

*Reviewer \#2:*

In this manuscript, using the LysM-Cre transgenic line or overexpressing the gene in RAW264.7 cells, Ng et al. showed that Rgs12 deletion led to increased bone mass whereas its overexpression increased OC number and size. Proteomic analysis of Rgs12-deficient OCs identified an upregulation of antioxidant enzymes under the transcriptional regulation of Nrf2, the master regulator of oxidative stress. They confirmed an increase of Nrf2 activity and impaired production of ROS in Rgs12- deficient cells. Conversely, Rgs12 overexpression suppressed Nrf2 through a mechanism dependent on the 26S proteasome, and promoted RANKL-induced phosphorylation of ERK1/2 and NFκB, which was abrogated by antioxidant treatment. In sum, the authors demonstrated a potentially novel upstream network for regulating osteoclastogenesis via the ROS pathway.

The authors have provided more insights into the role ROS plays in regulating osteoclastogenesis, clearly an important pathway in the differentiation process. The paper is well written and there is some novelty particularly in the mechanism through which Rgs12 mediates suppression of Nrf2 and that in turn, down regulates ROS via anti-oxidant factors. There are however some concerns (labelled 1-6) which are major and must be addressed; even though enthusiasm is moderate, more work is required to firmly establish the role of Rgs12 in osteoclast differentiation.

1\) The mechanism underlying attenuated osteoclastogenesis in the Rgs12 deletion model is presumed to be an upregulation of the Nrf2 anti-oxidant system. Yet it is unclear why Keap1 levels are high in the Rgs12 null cells particularly since Keap1 sequesters Nrf2 and prevents its action. A more comprehensive approach to understanding that feature beyond a theoretical compensatory response is needed to fully delineate the pathway\'s importance for osteoclastogenesis.

2\) On a similar note, it is unclear why Nrf2 protein levels are not increased in the proteomic analysis of the Rgs12 deleted cells, particularly since the downstream anti-oxidant proteins are increased, one would have expected those changes. Did the authors measure Nrf2 protein by WB in the Rgs12 null osteoclasts?

3\) The conditional deletion by LysMCre of Rgs12 led to high bone mass and presumed osteoclast dysfunction. The BMM cells during differentiation showed less nuclei and lower number of OCs; however the authors did not perform studies on the functional significance of this osteoclast phenotype; did the osteoclasts from the LysMCre mice resorb less bone in vitro i.e. on a bone matrix?

4\) In that same vein, there was no dynamic histomorphometry studies to assess the etiology of the high bone mass. An obvious conclusion would be that there is less resorption. However it would be important to have measured eroded surface, bone formation rates and other parameters that could be responsible for the high bone mass in the LysMCre Rgs12 deficient mice. Nor it should be noted were osteoclast numbers counted by static measurements. This needs clarification particularly if osteoclast number remained the same in the Rgs12 null mice, but the cells were not functional (less nuclei) and clastokines were still being released to stimulate osteoblasts as in the catK ko mice. Clearly more insight into the in vivo phenotype would have been preferable. Similarly, resorption markers and/or an OVX experiment would have also been useful.

5\) The proteomic analysis of the Rgs12 deficient osteoclasts revealed a shift toward more glycolytic pathways. This would be consistent with less ROS generation; but is it that shift that directly impairs osteoclast function? In other words, when osteoclasts become glycolytic, the cells cannot fuse or resorb bone? It is disappointing that the authors did not examine OxPhos and glycolytic patterns during OC differentiation in these cells to complete the characterization of their metabolic programs. Since the premise of the paper is the critical nature of ROS levels, defining their oxidative capacity would seem to be necessary.

6\) The NAC suppression of NFκB activation is not surprising; but is it specific for ROS mediated activation or does it have other downstream activity?

*Reviewer \#3:*

In this manuscript the authors examine the role that Rgs12 has in osteoclast formation and function. They find that targeted deletion of Rgs12 in myeloid cells produces a phenotype in mice of increased bone mass. In vitro studies of BMMs demonstrates that Rgs12 deletion decreased the number of osteoclasts that formed in vitro with 6 or greater nuclei with no effect on the number of osteoclasts that had 3 to 5 nuclei. Conversely, overexpression of Rgs12 in RAW264.7 cells increased the overall size of osteoclasts that formed in vitro and the number of osteoclasts with greater than 10 nuclei. Overexpression of Rgs12 also decreased the number of osteoclasts that had less than 10 nuclei in the RAW cell cultures.

Proteomic analysis identified Nrf2-mediated stress responses as potentially mediating the effects of Rgs12 deletion on osteoclastogenesis in vitro. Consequently, the authors studied the role that Rgs12 had in mediating responses of Nrf2 in osteoclasts. They found that deletion of Rgs12 increased levels of the transcription factor Nrf2, which is induced by oxidative stress, and its regulatory protein Keap1 in BMMs that were induced to form osteoclasts with RANKL. RANKL also increased the nuclear localization of Nrf2 in Rgs12-deleted cells, which is consistent with the decrease in osteoclastogenesis seen in Rgs12-deleted BMM cultures, since Nrf2 activation is known to inhibit osteoclast formation. RANKL did not stimulate oxidative stress in Rgs12-deleted BMM cultures, implying that the increased levels of Nrf2 stimulated an antioxidant pathway to reduce ROS levels.

Overexpression of Rgs12 in RAW cells reduced the ability of a Keap2 inhibitor (tBHQ) to induce Nrf2. To better understand how this might be occurring the authors examined the effects that the proteasome inhibitor, MG-132, had on Nrf2 levels in RAW cells in the presence or absence of Rgs12 overexpression. They found that in the absence of proteasome degradation, overexpression of Rgs12 did not inhibit Nrf2 protein levels but rather enhanced them suggesting that Rgs12 regulates interactions of the proteasome degradation pathway with Nrf2.

Finally, the authors demonstrated that pretreating RAW cells, which overexpressed Rgs12, with an antioxidant (to decrease ROS) inhibited ERK and NF-κB activation by RANKL. They conclude that this data implies that Rgs12 promotes ROS production as one mechanism for its ability to stimulate osteoclast formation and function.

This is a complex subject and the authors have attempted a variety of investigations to support their conclusions. In general, they have been successful but there are several criticisms that they need to address.

1\) The in vivo model of targeted deletion of Rgs12 in myeloid cells is lacking any evidence that this manipulation resulted in a decrease in osteoclast number or function in the mice. The authors need to perform histomorphometric studies to confirm that the increase in bone mass that they find with targeted Rgs12 deletion is associated with a decrease in osteoclast number, size or erosion surface. Studies of osteoblasts and bone formation rate are also needed.

2\) What is the effect of 1 to 5 days of RANKL treatment on levels of Rgs12 mRNA and protein in BMM cultures compared to cultures treated with M-CSF alone? This is a fundamental experiment that the authors do not present. Are levels increased, unchanged or decreased by RANKL? The authors seem to be arguing that RANKL increases Rgs12 levels since overexpression of this protein enhanced and deletion decreased RANKL-induced osteoclastogenesis. However, the authors really need to show this kind of data to confirm this hypothesis.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your article \"Regulator of G protein signaling 12 enhances osteoclastogenesis by suppressing Nrf2-dependent ROS generation\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The authors have responded to most of the comments and the paper is more comprehensive. We would like to move forward however, there are two sticking points of concern that you must address more completely:

1\) Figure 4A western is not at all convincing that deletion of Rgs12 increases Nrf2 activity and this is a major premise of the paper -- a critical figure; we would like to see the difference more clearly.

2\) The authors did NOT respond to the issue of the proper control for the LysMCre Rgs12 targeted deletion by skeletal phenotyping; the appropriate control is the LysMCreRgs12+/+, that should be relatively easy to phenotype and exclude a transgenic Cre effect. All that you say is that the animals are not different in size. It should be relatively straightforward since these are the controls to have bone density data.

10.7554/eLife.42951.020

Author response

\[Editors\' note: the authors' plan for revisions was approved and the authors made a formal revised submission.\]

> Reviewer \#1:
>
> This manuscript reports that deletion of Rgs12 in vivo increased bone mass and in vitro decreased osteoclastogenesis and ROS production and increased Nrf2 protein level and Nrf2-dependent antioxidant enzymes.
>
> 1\) The major conclusion of the paper, that Rgs12 deletion decreases osteoclast formation, needs to be tested in vivo by reporting quantitation of osteoclast and osteoblast numbers and activity in the histology shown in Figure 1C. The in vivo data also lacks an important control (LysM-cre;Rgs12+/+ mice) because cre expression can cause effects on bone phenotype even without the presence of a floxxed allele. The in vitro data also needs to be strengthened by measuring osteoclast activity (pit formation) rather than relying on osteoclast number and size.

A\) Quantitation of osteoclast and osteoblast numbers

Findings: Quantification of bone cells on femoral bone sections obtained from Rgs12fl/fl and LysM;Rgs12fl/fl mice show a significant decrease in osteoclast numbers as TRAP+ multinucleated cells and no changes to osteoblast numbers.

Manuscript revisions:

\- Experiments completed and incorporated into Figure 1 as panels J-M.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

B\) Measuring the rate of bone formation by dynamic histomorphometric analysis

Findings: Dynamic histomorphometric analysis by double calcein labeling showed no difference mineral apposition rate (MAR) nor bone formation rate (BFR) between Rgs12^fl/fl^ and LysM;Rgs12^fl/fl^ mice.

Manuscript revisions:

\- Experiments completed and data incorporated into Figure 1 as panels N-P.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

C\) Assessing the effects of Rgs12 deletion or overexpression on osteoclastic bone resorption

Findings: Rgs12-deleted osteoclast precursors cultured ex vivo showed significantly reduced bone resorption activity whereas Rgs12 overexpressed in RAW264.7 cells increased bone resorption.

Manuscript revisions:

\- Experiments completed and incorporated into Figure 2 as panels E-F and K-L.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

D\) LysM control

Cre expression can lead to phenotypes independent of the targeted gene, including skeletal phenotypes.^7^ Particularly, we have noted this phenomenon in mice with osterix promoter-driven Cre, which are dramatically smaller compared to their wild-type control, which has been documented by Huang and Oslen.^8^ On the contrary, we did not observe any differences in the size of LysM;Rgs12^+/+^ mice compared to the Rgs^fl/fl^ or wild type mice. An in-depth search of publications did not yield any reports of skeletal defects associated with the LysM-Cre transgenic line. Moreover, many published work using the LysM-Cre system also use floxed mice as control, and did not include the LysM-Cre;gene^+/+^ control.^9-14^ Therefore, it unlikely that LysM-Cre has a significant impact on the skeletal phenotype.

> 2\) The effects of Rgs12 deletion and overexpression on Rgs12 protein levels appear to be quite modest and not observable in the western blots, and their quantitation by densitometry is unlikely to be sensitive enough to reliably detect the small differences, which, even if true, are unlikely to be sufficient to have a major effect on the cellular phenotype. Moreover, no experiments were performed to test whether the altered Nrf2 levels cause the phenotype induced by Rgs12 deletion.

The deletion of Rgs12 in LysM;Rgs12^fl/fl^ BMMs resulted in approximately 70% reduction of Rgs12 transcript levels as measured by qPCR (Figure 1B). Additionally, the ectopic expression of Rgs12 in RAW264.7 cells led to an approximately doubled Rgs12 protein levels as measured by western blotting (Figure 2C).

The role of Nrf2 in osteoclasts and bone biology has been previously reported and is consistent with the findings reported in the current study. In osteoclasts, ROS is conducive towards its formation and bone resorption whereas antioxidants are inhibitory. Therefore, it should be expected that elevated Nrf2 activity and increased expression of antioxidant enzymes, as observed in Rgs12^--/--^ mice, would suppress osteoclast differentiation. Conversely, reduced Nrf2 activity should promote osteoclastogenesis. Supporting this idea, global Nrf2 knockout mice showed increased osteoclast numbers in distal femurs and increased osteoclast surface in lumbar vertebrae.^15^ Furthermore, Nrf2^--/--^ mice have reduced trabecular and cortical bone, along with a reduction in bone mechanical strength, although this may likely be attributed to reduced bone mineralization and formation by osteoblasts.^15-17^ As a confounding factor, Nrf2^--/--^ osteoblasts also have increased RANKL expression, thereby indirectly promoting osteoclast formation in Nrf2 global knockout mice.^18^ However, the direct role of Nrf2 in osteoclasts has been demonstrated. It was shown that RANKL stimulation of RAW264.7 cells lowers their Nrf2/Keap1 ratio and leads to a decrease in the expression of antioxidant response element (ARE) genes, whereas Nrf2 overexpression elevates antioxidant expression and suppresses osteoclast differentiation.^19-21^ Importantly, Nrf2 deficiency in osteoclasts promotes the RANKL-induced activation of MAPKs, c-Fos, and the subsequent induction of NFATc1.^21^ Therefore, it is clear that Nrf2 has a direct effect on osteoclasts. Whereas Nrf2 deficiencycontributes to heightened osteoclastic formation and a net bone loss phenotype,^15,18^ we observe the exact opposite in Rgs12 conditional knockout mice wherein Nrf2 activity was elevated.

> Reviewer \#2:
>
> \[...\] The paper is well written and there is some novelty particularly in the mechanism through which Rgs12 mediates suppression of Nrf2 and that in turn, down regulates ROS via anti-oxidant factors. There are however some concerns (labelled 1-6) which are major and must be addressed; even though enthusiasm is moderate, more work is required to firmly establish the role of Rgs12 in osteoclast differentiation.
>
> 1\) The mechanism underlying attenuated osteoclastogenesis in the Rgs12 deletion model is presumed to be an upregulation of the Nrf2 anti-oxidant system. Yet it is unclear why Keap1 levels are high in the Rgs12 null cells particularly since Keap1 sequesters Nrf2 and prevents its action. A more comprehensive approach to understanding that feature beyond a theoretical compensatory response is needed to fully delineate the pathway\'s importance for osteoclastogenesis.

Keap1 plays an important role for maintaining Nrf2 at low levels by acting as an adaptor protein for the Cullin-3-based ubiquitin E3 ligase, which mediates Nrf2 degradation via the 26S proteasome. While Keap1 levels appear to be elevated in Rgs12-deficient BMMs (Figure 4A, B), we also found that the Rgs12-mediated degradation of Nrf2 is independent of Keap1 function (Figure 5B, C). tBHQ (*tert*-butylhydroquinone) is a selective inhibitor of Keap1 and was shown to directly covalently modify cysteine residues on Keap1 to inhibit its activity,^22^ but it was unable to block Rgs12-mediated degradation of Nrf2. We subsequently showed that Rgs12 is likely to regulate the interactions of the proteasome degradation pathway with Nrf2. Therefore, while Keap1 certainly plays a canonical role in Nrf2 suppression, the evidence suggests that Keap1 is not involved in the Rgs12 function.

> 2\) On a similar note, it is unclear why Nrf2 protein levels are not increased in the proteomic analysis of the Rgs12 deleted cells, particularly since the downstream anti-oxidant proteins are increased, one would have expected those changes. Did the authors measure Nrf2 protein by WB in the Rgs12 null osteoclasts?

The upregulation of Nrf2-dependent antioxidant enzymes certainly points toward increased Nrf2 protein levels. However, the transcription factor was not detected in the proteomics analysis, which is likely a result of technical factors inherent to current LC-MS capabilities. It was previously reported that transcription factor protein levels are notoriously difficult to obtain due to many having relatively low expression levels that are generally below current mass spectrometer detection limits.^23^ The quantitation of transcription factors typically entails an upstream enrichment/separation step before LC-MS analysis. Therefore, the absence of Nrf2 in our proteomics analysis is not an unusual happenstance from a technical standpoint. Alternatively, we confirmed our proteomics findings by showing increased Nrf2 protein levels and nuclear translocation activity in Rgs12-deficient osteoclasts (Figure 4A-C)

Technical reasons that could explain why Nrf2 was not detected in the LC-MS analysis as described above was added to the Discussions section.

> 3\) The conditional deletion by LysMCre of Rgs12 led to high bone mass and presumed osteoclast dysfunction. The BMM cells during differentiation showed less nuclei and lower number of OCs; however the authors did not perform studies on the functional significance of this osteoclast phenotype; did the osteoclasts from the LysMCre mice resorb less bone in vitro i.e. on a bone matrix?

We assessed the effects of Rgs12 deletion on osteoclastic bone resorption. Osteoclasts derived from BMMs isolated from Rgs12^fl/fl^ and LysM;Rgs12^fl/fl^ mice was differentiated on calcium phosphate-coated plates. Resorptive activity was measured as a function of the percentage area of calcium phosphate removed relative to the total area.

Findings: Rgs12-deleted osteoclast precursors cultured ex vivo showed significantly reduced bone resorption activity whereas Rgs12 overexpressed in RAW264.7 cells increased bone resorption.

Manuscript revisions:

\- Experiments completed and incorporated into Figure 2 as panels E-F and K-L.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

> 4\) In that same vein, there was no dynamic histomorphometry studies to assess the etiology of the high bone mass. An obvious conclusion would be that there is less resorption. However it would be important to have measured eroded surface, bone formation rates and other parameters that could be responsible for the high bone mass in the LysMCre Rgs12 deficient mice. Nor it should be noted were osteoclast numbers counted by static measurements. This needs clarification particularly if osteoclast number remained the same in the Rgs12 null mice, but the cells were not functional (less nuclei) and clastokines were still being released to stimulate osteoblasts as in the catK ko m. Clearly more insight into the in vivo phenotype would have been preferable. Similarly, resorption markers and/or an OVX experiment would have also been useful.

We addressed this issue by measuring the rate of bone formation by dynamic histomorphometric analysis. 12 week-old Rgs12^fl/fl^ and LysM;Rgs12^fl/fl^ mice will be given two doses of calcein label 5-7 days apart, by intraperitoneal injection. Femurs were isolated and visualized by fluorescence imaging and the mineral apposition rate (MAR) and bone formation rate (BFR) were determined. Additionally, femoral sections were stained and bone cells were quantified.

A\) Measuring the rate of bone formation by dynamic histomorphometric analysis

Findings: Dynamic histomorphometric analysis by double calcein labeling showed no difference mineral apposition rate (MAR) nor bone formation rate (BFR) between Rgs12^fl/fl^ and LysM;Rgs12^fl/fl^ mice.

Manuscript revisions:

\- Experiments completed and data incorporated into Figure 1 as panels N-P.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

B\) Quantitation of osteoclast and osteoblast numbers

Findings: Quantification of bone cells on femoral bone sections obtained from Rgs12fl/fl and LysM;Rgs12fl/fl mice show a significant decrease in osteoclast numbers as TRAP+ multinucleated cells and no changes to osteoblast numbers.

Manuscript revisions:

\- Experiments completed and incorporated into Figure 1 as panels J-M.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

> 5\) The proteomic analysis of the Rgs12 deficient osteoclasts revealed a shift toward more glycolytic pathways. This would be consistent with less ROS generation; but is it that shift that directly impairs osteoclast function? In other words, when osteoclasts become glycolytic, the cells cannot fuse or resorb bone? It is disappointing that the authors did not examine OxPhos and glycolytic patterns during OC differentiation in these cells to complete the characterization of their metabolic programs. Since the premise of the paper is the critical nature of ROS levels, defining their oxidative capacity would seem to be necessary.

We probed into the possible involvement of metabolic programs and redox homeostasis through literature and our proteomics data, detailed below. This important consideration incorporated into the Discussion section. Proteomics data detailing proteins in bioenergetic programs were extracted into an Excel sheet as added as Figure 3---figure supplement 1. Pathway analysis diagrams corresponding to glycolysis, TCA cycle, and OXPHOS pathways were added as Figure 3---figure supplement 2.

Hypothesis: The inhibition of RANKL-dependent ROS associated with loss of Rgs12 is not the direct result of glycolytic shift or reduced oxidative phosphorylation.

Text added to the Discussion section (eighth paragraph):

ROS is an inevitable byproduct of the mitochondrial electron transport chain (oxidative phosphorylation, OXPHOS) during ATP synthesis. \[...\] Therefore, changes in mitochondrial ROS could certainly be an aspect of Rgs12 function, but Nrf2 remains an essential requirement in the overall scheme.

> 6\) The NAC suppression of NFκB activation is not surprising; but is it specific for ROS mediated activation or does it have other downstream activity?

N-acetylcysteine (NAC) is a generally thought to provide the precursor substrate (~L~-cysteine) for the synthesis of glutathione (GSH), an important thiol-containing antioxidant protein.^24^ NAC has been shown in several studies to cause the inactivation of ERK, JNK, and p38 MAPK, and inhibit osteoclast formation, presumably through its antioxidant capability.^25,26^ Additionally, NAC supplementation in mice leads to decreased osteoclast differentiation and increased bone mass,^27^ which could also be substantiated by reduced RANKL production as seen in a study of IL-17-induced RANKL production in rheumatoid arthritis synovial fibroblasts.^28^ In our study, the key purpose of NAC was to show that the Rgs12-dependent phosphorylation of ERK1/2 and NFκB was dependent on ROS (Figure 6A-B). However, as with any study using small-molecule inhibitors, off-target effects are a reasonable concern. To the point of whether NAC has other functions outside of its antioxidant role, recent findings have shown that it could directly antagonize the activity of proteasome inhibitors (bortezomib, lactacystin, and MG132).^29,30^ This would of course have significant implications in proteasome-dependent proteins such as NFκB (via IκBα degradation) and Nrf2---*if* NAC was used together with proteasome inhibitors. Importantly, NAC itself is not an agonist of proteasome function.^30^ Within the context of our study, NAC alone could attenuate ERK1/2 and NFκB activation, likely as a result of its antioxidant function.

> Reviewer \#3:
>
> \[...\] This is a complex subject and the authors have attempted a variety of investigations to support their conclusions. In general, they have been successful but there are several criticisms that they need to address.
>
> 1\) The in vivo model of targeted deletion of Rgs12 in myeloid cells is lacking any evidence that this manipulation resulted in a decrease in osteoclast number or function in the mice. The authors need to perform histomorphometric studies to confirm that the increase in bone mass that they find with targeted Rgs12 deletion is associated with a decrease in osteoclast number, size or erosion surface. Studies of osteoblasts and bone formation rate are also needed.

A\) Quantitation of osteoclast and osteoblast numbers

Findings: Quantification of bone cells on femoral bone sections obtained from Rgs12fl/fl and LysM;Rgs12fl/fl mice show a significant decrease in osteoclast numbers as TRAP+ multinucleated cells and no changes to osteoblast numbers.

Manuscript revisions:

\- Experiments completed and incorporated into Figure 1 as panels J-M.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

B\) Measuring the rate of bone formation by dynamic histomorphometric analysis

Findings: Dynamic histomorphometric analysis by double calcein labeling showed no difference mineral apposition rate (MAR) nor bone formation rate (BFR) between Rgs12^fl/fl^ and LysM;Rgs12^fl/fl^ mice.

Manuscript revisions:

\- Experiments completed and data incorporated into Figure 1 as panels N-P.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

C\) Assessing the effects of Rgs12 deletion or overexpression on osteoclastic bone resorption

Findings: Rgs12-deleted osteoclast precursors cultured ex vivo showed significantly reduced bone resorption activity whereas Rgs12 overexpressed in RAW264.7 cells increased bone resortion.

Manuscript revisions:

\- Experiments completed and incorporated into Figure 2 as panels E-F and K-L.

\- Data used to update Results section.

\- Discussion updated.

\- New methodology added to Methods section.

> 2\) What is the effect of 1 to 5 days of RANKL treatment on levels of Rgs12 mRNA and protein in BMM cultures compared to cultures treated with M-CSF alone? This is a fundamental experiment that the authors do not present. Are levels increased, unchanged or decreased by RANKL? The authors seem to be arguing that RANKL increases Rgs12 levels since overexpression of this protein enhanced and deletion decreased RANKL-induced osteoclastogenesis. However, the authors really need to show this kind of data to confirm this hypothesis.

To address this gap, we measured Rgs12 expression during osteoclast differentiation. BMMs obtained from either LysM;Rgs12^+/+^ or Rgs12^fl/fl^ mice was differentiated using M-CSF and RANKL for up to 5 days. Rgs12 transcript and protein levels at different time-points of differentiation were measured by qPCR and western blotting, respectively.

Findings: Rgs12 expression as measured by western blotting and qPCR was increased over the course of osteoclast differentiation.

Manuscript Revisions:

\- Experiments completed and data incorporated into Figure 2 as panels A-B.

\- Data used to update Results section.
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> \[Editors\' note: further revisions were requested prior to acceptance, as described below.\]
>
> 1\) Figure 4A western is not at all convincing that deletion of Rgs12 increases Nrf2 activity and this is a major premise of the paper -- a critical figure; we would like to see the difference more clearly

A better quality western blot was substituted into Figure 4A.

> 2\) The authors did NOT respond to the issue of the proper control for the LysMCre Rgs12 targeted deletion by skeletal phenotyping; the appropriate control is the LysMCreRgs12+/+, that should be relatively easy to phenotype and exclude a transgenic Cre effect. All that you say is that the animals are not different in size. It should be relatively straightforward since these are the controls to have bone density data.

To exclude a possible transgenic Cre effect, we characterized and compared the bone histomorphometry of *LyzM^Cre^;Rgs12^+/+^* and *Rgs12^flox/flox^* mice, and found no statistical difference in the quantitative micro-CT measurements. Therefore, either of these mouse genotypes would be suitable as negative controls in this study. This finding was updated in the manuscript (subsection "Targeted deletion of Rgs12 selectively reduced osteoclast formation and increased trabecular bone mass", first paragraph).

Data added as Figure 1---figure supplement 1. Corresponding figure legend added to manuscript.

Data added to Figure 1---source data.
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